Refine
Language
- English (23)
Has Fulltext
- yes (23)
Is part of the Bibliography
- no (23)
Keywords
- SARS-CoV-2 (4)
- COVID-19 (2)
- microbiome (2)
- AML (1)
- Antibiotics (1)
- Antiretroviral therapy (1)
- B.1.617.1 (1)
- B.1.617.2 (1)
- BNT2b2 (1)
- Bacteria (1)
- Bloodstream infection (1)
- CDI (1)
- CRP (1)
- Cancer (1)
- Catheters (1)
- Clostridioides difficile (1)
- Cluster (1)
- Colonisation (1)
- Contact precautions (1)
- D-dimer (1)
- DST (1)
- Drug susceptibility testing (1)
- Epsilon (1)
- Gene sequencing (1)
- Gut bacteria (1)
- HIV (1)
- Hematology (1)
- Induction chemotherapy (1)
- Infection control (1)
- Influenza (1)
- Kappa (1)
- M. Intracellulare (1)
- M. avium (1)
- M. avium complex (1)
- M. chimaera (1)
- Microbiome (1)
- Multidrug-resistant bacteria (1)
- Mycobacteria (1)
- Mycobacterium avium complex (1)
- NAFL (1)
- NASH (1)
- NTM (1)
- Non-tuberculous mycobacteria (1)
- Nontuberculous mycobacteria (1)
- Oncology (1)
- Opportunistic infections (1)
- Parainfluenza (1)
- Pneumonia (1)
- Protease inhibitor therapy (1)
- Respiratory infections (1)
- Respiratory syncytial virus (1)
- Ribosomal RNA (1)
- Superinfection (1)
- Upper respiratory tract infection (1)
- Urine (1)
- acute-on-chronic liver failure (1)
- ascites (1)
- bacteriophages (1)
- cirrhosis (1)
- comorbidities (1)
- corona virus (1)
- critically ill patients (1)
- cytokines (1)
- delta (1)
- diagnostic algorithm (1)
- dysbiosis (1)
- faecal microbiota transfer (1)
- fecal microbiota transfer (1)
- fidaxomicin (1)
- graft-vs-host disease (1)
- gut microbiota (1)
- human allogeneic hematopoietic cell transplantation (1)
- human intestinal microbiota (1)
- infection (1)
- lasso regression (1)
- lung disease (1)
- mRNA1273 (1)
- miRNA (1)
- monoclonal antibodies (1)
- myeloid cells (1)
- neurological manifestations (1)
- nomogram (1)
- preventive strategies (1)
- recurrent urinary tract infections (1)
- respiratory failure (1)
- risk factors (1)
- systemic inflammation (1)
- vaccination (1)
- vancomycin (1)
Institute
- Medizin (23) (remove)
The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections. We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.427/B.1.429 (Epsilon), all harboring the spike substitution L452R. We found that authentic SARS-CoV-2 variants harboring L452R had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to B.1, Kappa and Delta showed a reduced neutralization by convalescent sera by a factor of 8.00 and 5.33, respectively, which constitutes a 2-fold greater reduction when compared to Epsilon. BNT2b2 and mRNA1273 vaccine-elicited sera were less effective against Kappa, Delta, and Epsilon compared to B.1. No difference was observed between Kappa and Delta towards vaccine-elicited sera, whereas convalescent sera were 1.51-fold less effective against Delta, respectively. Both B.1.617 variants Kappa (+E484Q) and Delta (+T478K) were less susceptible to either casirivimab or imdevimab. In conclusion, in contrast to the parallel circulating Kappa variant, the neutralization efficiency of convalescent and vaccine-elicited sera against Delta was moderately reduced. Delta was resistant to imdevimab, which, however, might be circumvented by combination therapy with casirivimab together.
Objectives: To discuss optimal management of recurrent urinary tract infections (UTIs) in women. About every second woman experiences at least one UTI in her lifetime, of those 30% experience another UTI, and 3% further recurrences. Especially young healthy women without underlying anatomical deficiencies suffer from recurrent UTIs (rUTI), which are associated with significant morbidity and reduction in quality of life.
Methods: This is a narrative review, investigating publications dealing with recurrent UTI in women. Risk factors and options for management are discussed.
Results: The increased susceptibility of women to rUTI is based on the female anatomy in addition to behavioural, genetic, and urological factors. However, why some women are more likely than others to develop and maintain rUTI remains to be clarified. Invasive characteristics of certain uropathogenic Escherichia coli that are able to form extra- and intracellular biofilms and may therefore cause delayed release of bacteria into the bladder, may play a role in this setting. Treatment recommendations for an acute episode of rUTI do not differ from those for isolated episodes. Given the nature of rUTI, different prophylactic approaches also play an important role. Women with rUTI should first be counselled to use non-antibiotic strategies including behavioural changes, anti-adhesive treatments, antiseptics, and immunomodulation, before antibiotic prophylaxis is considered. In addition to the traditional treatment and prophylactic therapies, new experimental strategies are emerging and show promising effects, such as faecal microbiota transfer (FMT), a treatment option that transfers microorganisms and metabolites of a healthy donor’s faecal matter to patients using oral capsules, enemas, or endoscopy. Initial findings suggest that FMT might be a promising treatment approach to interrupt the cycle of rUTI. Furthermore, bacteriophages, infecting and replicating in bacteria, have been clinically trialled for UTIs.
Conclusion: Due to the limitation of available data, novel treatment options require further clinical research to objectify the potential in treating bacterial infections, particularly UTIs.
The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections.
We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.427/B.1.429 (Epsilon), all harboring the spike substitution L452R.
We found that authentic SARS-CoV-2 variants harboring L452R had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to B.1, Kappa and Delta showed a reduced neutralization by convalescent sera by a factor of 8.00 and 5.33, respectively, which constitutes a 2-fold greater reduction when compared to Epsilon. BNT2b2 and mRNA1273 vaccine-elicited sera were less effective against Kappa, Delta, and Epsilon compared to B.1. No difference was observed between Kappa and Delta towards vaccine-elicited sera, whereas convalescent sera were 1.5-fold less effective against Delta, respectively. Both B.1.617 variants Kappa (+E484Q) and Delta (+T478K) were less susceptible to either casirivimab or imdevimab.
In conclusion, in contrast to the parallel circulating Kappa variant, the neutralization efficiency of convalescent and vaccine-elicited sera against Delta was moderately reduced. Delta was resistant to imdevimab, which however, might be circumvented by a combination therapy with casirivimab together.